Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.30 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.30 |
| ▸ | CASR | P41180 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6334600 | 0.93 | SLC6A2 (0.30) | — | |
| Hydrochloric Acid SCHEMBL6334950 | 0.89 | LTA4H (0.31) | LTA4H | |
| Hydrochloric Acid SCHEMBL6332280 | 0.87 | SLC6A2 (0.34) | PPARGPPARA | |
| Hydrochloric Acid SCHEMBL6334559 | 0.82 | ABCB1 (0.34) | HTR2A | |
| Hydrochloric Acid SCHEMBL6338936 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL6332728 | 0.80 | ABCB1 (0.31) | — | |
| Hydrochloric Acid SCHEMBL6333045 | 0.79 | ABCB1 (0.32) | — | |
| Hydrochloric Acid SCHEMBL6330209 | 0.78 | MEN1 (0.34) | PPARG | |
| Hydrochloric Acid SCHEMBL6338577 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL6332903 | 0.76 | HTT (0.38) | HTR2AOPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6870017-B2 | Transition metal compound, catalyst for addition polymerization, and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-03-22 | — | — | US | disclosed |
| CN-1174002-C | Transition metal compound, catalyst for polyaddition and method for preparing addition polymer | 住友化学工业株式会社 | 2004-11-03 | — | — | CN | disclosed |
| US-20030171212-A1 | Transition metal compound, catalyst for addition polymerization, and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED | 2003-09-11 | — | — | US | disclosed |
| US-6548686-B2 | Coordination catalysts; suppresses heat generation | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-04-15 | — | — | US | disclosed |
| US-20020013433-A1 | Transition metal compound, catalyst for addition polymerization, and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013433-A1 | Transition metal compound, catalyst for addition polymerization, and process for producing addition polymer | ASH2L, ARL1, AS3MT | HTR2A 4645/4885PPARG 3775/4885PPARA 3191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.